NKTR
Nektar Therapeutics NASDAQ Listed May 3, 1994$83.37
After hrs
$81.89
+0.00%
Mkt Cap $1.7B
52w Low $7.99
74.6% of range
52w High $109.00
50d MA $77.64
200d MA $54.67
P/E (TTM)
-8.9x
EV/EBITDA
-6.5x
P/B
16.2x
Debt/Equity
1.7x
ROE
-182.7%
P/FCF
-3.4x
RSI (14)
—
ATR (14)
—
Beta
1.18
50d MA
$77.64
200d MA
$54.67
Avg Volume
1.3M
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
455 Mission Bay Boulevard South · San Francisco, CA 94158 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -2.76 | -1.78 | +35.5% | 70.36 | +3.2% | +4.1% | +2.6% | +6.7% | +4.0% | +6.4% | — |
| Nov 6, 2025 | AMC | -2.85 | -1.85 | +35.1% | 55.12 | +1.6% | +1.5% | +5.2% | +7.5% | +4.6% | -2.1% | — |
| Aug 7, 2025 | AMC | -3.13 | -2.95 | +5.8% | 21.75 | +3.9% | +6.0% | +3.3% | +8.5% | +18.3% | +22.7% | — |
| May 8, 2025 | AMC | -2.70 | -3.30 | -22.2% | 9.28 | -3.3% | -4.8% | +4.0% | +3.3% | +4.1% | -1.1% | — |
| Mar 12, 2025 | AMC | -1.95 | -2.25 | -15.4% | 12.30 | +6.9% | -0.6% | +9.3% | +10.9% | +7.3% | +9.4% | — |
| Nov 7, 2024 | AMC | -0.23 | -0.18 | +21.7% | 20.55 | +0.7% | +2.2% | +0.0% | -4.4% | -6.6% | -14.6% | — |
| Aug 8, 2024 | AMC | -0.21 | -0.25 | -19.0% | 18.15 | -4.1% | -8.3% | -8.3% | -5.0% | -5.8% | -1.7% | — |
| May 9, 2024 | AMC | -0.21 | -0.18 | +14.3% | 24.00 | +3.1% | +10.0% | +9.4% | +10.6% | +14.4% | +12.5% | — |
| Mar 4, 2024 | AMC | -0.20 | -0.22 | -10.0% | 13.50 | -1.0% | -1.8% | +1.1% | +6.1% | +1.0% | -7.6% | — |
| Nov 7, 2023 | AMC | -0.18 | -0.19 | -5.6% | 8.22 | -3.0% | -8.8% | -13.3% | -17.0% | -18.0% | -6.9% | — |
| Aug 8, 2023 | AMC | -0.30 | -0.27 | +10.0% | 15.00 | -8.0% | -9.0% | +5.0% | -7.0% | -18.0% | -19.0% | — |
| May 9, 2023 | AMC | -0.26 | -0.25 | +3.8% | 11.55 | +2.6% | -2.6% | -3.9% | -5.2% | -1.3% | -6.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | Wedbush | Maintains | Neutral → Neutral | — | $100.35 | $103.00 | +2.6% | -2.2% | -7.1% | -9.1% | -8.6% | -13.6% |
| Apr 21 | Citigroup | Maintains | Buy → Buy | — | $100.35 | $103.00 | +2.6% | -2.2% | -7.1% | -9.1% | -8.6% | -13.6% |
| Apr 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $84.86 | $97.48 | +14.9% | +18.3% | +15.7% | +9.8% | +7.5% | +8.0% |
| Apr 20 | BTIG | Maintains | Buy → Buy | — | $84.86 | $97.48 | +14.9% | +18.3% | +15.7% | +9.8% | +7.5% | +8.0% |
| Mar 16 | Citigroup | Maintains | Buy → Buy | — | $73.25 | $75.38 | +2.9% | -1.4% | +2.5% | -0.1% | +2.2% | -1.4% |
| Feb 23 | B. Riley Securities | Maintains | Buy → Buy | — | $73.73 | $73.50 | -0.3% | -0.1% | -7.2% | -4.6% | -10.6% | -6.4% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.07 | $47.15 | +27.2% | +51.1% | +79.0% | +91.5% | +92.4% | +99.1% |
| Feb 10 | BTIG | Maintains | Buy → Buy | — | $37.07 | $47.15 | +27.2% | +51.1% | +79.0% | +91.5% | +92.4% | +99.1% |
| Jan 29 | BTIG | Maintains | Buy → Buy | — | $35.91 | $35.65 | -0.7% | -1.9% | +4.0% | +6.2% | +8.2% | +4.8% |
| Dec 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $53.30 | $48.68 | -8.7% | -7.8% | -14.8% | -17.4% | -12.1% | -18.4% |
| Dec 16 | BTIG | Maintains | Buy → Buy | — | $53.30 | $48.68 | -8.7% | -7.8% | -14.8% | -17.4% | -12.1% | -18.4% |
| Nov 26 | Jefferies | Maintains | Buy → Buy | — | $60.35 | $63.10 | +4.6% | +8.8% | +8.1% | +1.3% | -9.1% | -5.3% |
| Sep 23 | B. Riley Securities | Maintains | Buy → Buy | — | $58.89 | $59.10 | +0.4% | +1.2% | +2.4% | -5.6% | -0.7% | +0.1% |
| Sep 19 | BTIG | Maintains | Buy → Buy | — | $58.76 | $58.76 | +0.0% | -6.2% | +0.2% | +1.4% | +2.7% | -5.3% |
| Jul 8 | B. Riley Securities | Maintains | Buy → Buy | — | $23.47 | $23.81 | +1.4% | -3.2% | -0.5% | +6.9% | +6.6% | +4.0% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.54 | $19.92 | +108.8% | +156.3% | +205.2% | +211.1% | +170.0% | +170.9% |
| Apr 11 | Jefferies | Upgrade | Hold → Buy | — | $7.49 | $8.08 | +7.9% | +23.8% | +21.0% | +27.8% | +21.5% | +27.5% |
| Mar 14 | Oppenheimer | Upgrade | Perform → Outperform | — | $12.23 | $13.50 | +10.4% | +10.0% | +11.5% | +7.9% | +10.1% | +7.1% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.30 | $13.15 | +6.9% | -0.6% | +9.3% | +10.9% | +7.3% | +9.4% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.68 | $12.38 | -2.4% | +3.0% | -7.7% | -5.8% | -0.6% | -5.1% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.45 | $15.15 | -1.9% | -6.7% | -12.6% | -12.1% | -13.4% | -13.4% |
| Mar 6 | Jefferies | Maintains | Hold → Hold | — | $13.26 | $13.20 | -0.5% | +2.9% | +8.1% | +2.9% | -5.9% | +0.7% |
| Nov 9 | TD Cowen | Upgrade | Market Perform → Outperform | — | $7.50 | $8.00 | +6.7% | -4.9% | -9.1% | -10.1% | +2.0% | +5.1% |
| May 10 | Jefferies | Upgrade | Underperform → Hold | — | $11.55 | $11.85 | +2.6% | -2.6% | -3.9% | -5.2% | -1.3% | -6.5% |
| Mar 6 | Oppenheimer | Maintains | Perform → Perform | — | $23.55 | $23.55 | +0.0% | -8.3% | -15.3% | -19.1% | -22.3% | -24.2% |
| Feb 27 | Goldman Sachs | Maintains | Sell → Sell | — | $22.35 | $21.75 | -2.7% | -6.7% | -7.4% | +1.3% | +3.4% | +5.4% |
| Feb 24 | Jefferies | Downgrade | Hold → Underperform | — | $44.40 | $26.55 | -40.2% | -49.7% | -53.0% | -53.4% | -49.0% | -48.0% |
| Feb 24 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $44.40 | $26.55 | -40.2% | -49.7% | -53.0% | -53.4% | -49.0% | -48.0% |
| Aug 8 | JP Morgan | Downgrade | Neutral → Underweight | — | $73.20 | $68.55 | -6.4% | -0.2% | -3.5% | -0.6% | +1.4% | +5.3% |
| Apr 18 | Goldman Sachs | Downgrade | Neutral → Sell | — | $92.40 | $60.00 | -35.1% | -23.1% | -24.8% | -24.4% | -26.9% | -26.0% |
| Apr 18 | Mizuho | Maintains | Neutral → Neutral | — | $92.40 | $60.00 | -35.1% | -23.1% | -24.8% | -24.4% | -26.9% | -26.0% |
| Apr 18 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $92.40 | $60.00 | -35.1% | -23.1% | -24.8% | -24.4% | -26.9% | -26.0% |
| Mar 16 | Canaccord Genuity | Maintains | Buy → Buy | — | $67.20 | $67.05 | -0.2% | +3.3% | +23.7% | +25.0% | +27.0% | +35.7% |
| Mar 15 | Mizuho | Downgrade | Buy → Neutral | — | $62.40 | $59.25 | -5.0% | +7.7% | +11.3% | +33.2% | +34.6% | +36.8% |
| Mar 15 | Cowen & Co. | Downgrade | Outperform → Market Perform | — | $62.40 | $59.25 | -5.0% | +7.7% | +11.3% | +33.2% | +34.6% | +36.8% |
| Mar 15 | BTIG | Downgrade | Buy → Neutral | — | $62.40 | $59.25 | -5.0% | +7.7% | +11.3% | +33.2% | +34.6% | +36.8% |
| Mar 15 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $62.40 | $59.25 | -5.0% | +7.7% | +11.3% | +33.2% | +34.6% | +36.8% |
| Mar 14 | BofA Securities | Downgrade | Neutral → Underperform | — | $159.45 | $75.00 | -53.0% | -60.9% | -57.9% | -56.4% | -47.9% | -47.3% |
| Mar 9 | Oppenheimer | Upgrade | Perform → Outperform | — | $155.10 | $163.05 | +5.1% | +6.9% | +5.7% | +2.8% | -59.8% | -56.7% |
| Nov 8 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $201.75 | $209.10 | +3.6% | +8.9% | +2.8% | +1.0% | +0.7% | -0.7% |
| Nov 8 | Benchmark | Upgrade | Hold → Buy | — | $201.75 | $209.10 | +3.6% | +8.9% | +2.8% | +1.0% | +0.7% | -0.7% |
| Nov 5 | Oppenheimer | Maintains | Perform → Perform | — | $249.75 | $211.65 | -15.3% | -19.2% | -12.0% | -17.0% | -18.4% | -18.6% |
| Sep 10 | BofA Securities | Maintains | Neutral → Neutral | — | $236.70 | $236.85 | +0.1% | +1.1% | +3.7% | +1.2% | +2.5% | +3.0% |
| Aug 6 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $238.05 | $239.85 | +0.8% | -0.6% | -2.3% | -5.5% | -9.6% | -9.9% |
| Jun 28 | Stifel | Upgrade | Hold → Buy | — | $259.05 | $271.80 | +4.9% | +2.8% | +0.8% | -0.6% | +1.4% | -0.9% |
| May 10 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $301.50 | $302.55 | +0.3% | -1.8% | -4.0% | -7.6% | -6.2% | -5.6% |
| Apr 6 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $301.20 | $307.65 | +2.1% | +0.8% | -2.3% | -4.2% | -7.2% | -7.0% |
| Feb 22 | Benchmark | Downgrade | Buy → Hold | — | $373.80 | $362.40 | -3.0% | -10.5% | -9.6% | -8.6% | -10.0% | -8.9% |
| Jan 6 | Stifel | Maintains | Hold → Hold | — | $269.70 | $264.45 | -1.9% | -2.5% | +3.4% | +6.8% | +4.2% | +5.8% |
| Nov 12 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $256.65 | $258.00 | +0.5% | +0.2% | +0.9% | -0.9% | +2.6% | +0.0% |
No insider trades available.
8-K
Nektar Therapeutics -- 8-K Filing
Nektar Therapeutics completed a registered direct offering that became effective November 12, 2025, with supplemental prospectus documentation filed April 21, 2026, indicating capital raise activity for the biotech company.
Apr 23
8-K · 7.01
! Medium
Nektar Therapeutics -- 8-K 7.01: Regulation FD Disclosure
Nektar Therapeutics reported positive 52-week topline results from its REZOLVE-AA trial of rezpegaldesleukin for severe alopecia areata, potentially supporting future regulatory submissions for this novel treatment.
Apr 20
8-K · 7.01
! Medium
Nektar Therapeutics -- 8-K 7.01: Regulation FD Disclosure
Nektar Therapeutics reported approximately $741.7 million in cash and investments as of April 1, 2026, indicating a solid liquidity position to fund operations and potential investments.
Apr 20
8-K
Unknown — 8-K Filing
Nektar's Q4 2025 earnings announcement indicates the company remains focused on cash management during development stages, critical for biotechs burning capital while awaiting clinical trial outcomes and regulatory approvals.
Mar 12
8-K
Nektar Therapeutics -- 8-K Filing
Nektar Therapeutics will raise approximately $432 million in net proceeds from a public offering expected to close February 13, 2026, providing capital for operations and strategic initiatives.
Feb 13
8-K · 7.01
! Medium
Nektar Therapeutics -- 8-K 7.01: Regulation FD Disclosure
Nektar Therapeutics reported $229.1 million in cash and marketable securities as of January 31, 2026, indicating sufficient liquidity for near-term operations and development initiatives.
Feb 10
8-K · 7.01
! Medium
Nektar Therapeutics -- 8-K 7.01: Regulation FD Disclosure
Nektar Therapeutics reported positive 36-week interim results from its REZOLVE-AD trial of rezpegaldesleukin for moderate-to-severe atopic dermatitis, potentially advancing the candidate's regulatory pathway.
Feb 10
Data updated apr 26, 2026 3:12pm
· Source: massive.com